NYSEAMERICAN:VNRX traded up $0.03 on Friday, hitting $2.73. The stock had a trading volume of 15,304 shares, compared to its average volume of 108,530. VolitionRX has a 52 week low of $1.44 and a 52 week high of $4.00.
VolitionRX (NYSEAMERICAN:VNRX) last announced its quarterly earnings results on Wednesday, November 7th. The medical research company reported ($0.14) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.14).
An institutional investor recently bought a new position in VolitionRX stock. Leisure Capital Management acquired a new position in VolitionRX Ltd (NYSEAMERICAN:VNRX) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 72,479 shares of the medical research company’s stock, valued at approximately $188,000. Leisure Capital Management owned about 0.21% of VolitionRX as of its most recent SEC filing.
VolitionRX Company Profile
VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers worldwide. The company develops 39 epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. VolitionRX Limited is based in Singapore.
Featured Article: Investing in Growth Stocks
Receive News & Ratings for VolitionRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX and related companies with MarketBeat.com's FREE daily email newsletter.